Navigation Links
NicOx Reports First Quarter 2008 Financial Results
Date:5/14/2008

SOPHIA ANTIPOLIS, France, May 14 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today reported financial results for the first three months of 2008. On March 31, 2008, the Company had cash, cash equivalents and financial instruments of euro 153.7 million, compared to euro 201.2 million on March 31, 2007.

Revenues were euro 1.4 million in the first quarter of 2008, compared to euro 8.7 million for the corresponding period of 2007. The higher revenues achieved in Q1 2007 were principally due to two milestone payments from Merck & Co., Inc. and Pfizer Inc which were fully recognized during that period.

Operating expenses were euro 17.5 million in the first quarter of 2008, compared to euro 10.1 million in the first quarter of 2007. This increase in operating expenses was mainly due to the ongoing phase 3 clinical studies for naproxcinod, NicOx' lead investigational drug and the first compound in the CINOD class, for the treatment of the signs and symptoms of osteoarthritis.

In the first quarter of 2008, NicOx recorded a net loss of euro 13 million. This compares to a net profit of euro 1.8 million for the first quarter of 2007.

Key operational highlights - first quarter 2008

-- NicOx initiated two large Ambulatory Blood Pressure Monitoring (ABPM)

studies for naproxcinod in hypertensive patients with osteoarthritis.

These two large clinical pharmacology studies in the United States will

assess the blood pressure profile of naproxcinod in comparison to

ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring

(ABPM) technique. These two trials are 12 and 16 weeks in duration and

together are expected to recruit around 420 osteoarthritis patients

with controlled hypertension. Results of both studies are projected in

the fourth quarter of 2008

-- Pfizer Inc signed an extension of its March 2006 ophthalmology research

agr
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
2. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
3. IRIDEX Reports First Quarter 2008 Financial Results
4. Cardiome Reports First Quarter Results
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. Health Plan Execs Receive Smaller Bonuses as Companies Push Performance-Based Pay, HPW Reports; Hanway Tops Others in Total Compensation
7. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
8. Med-Emerg International Inc. reports improved income from continuing operations
9. NxStage Medical Reports First Quarter 2008 Results
10. MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results
11. ULURU Inc. Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... CA (PRWEB) March 02, 2015 Gummy ... gum reshaping procedures. Gum reshaping can involve one or several ... to regenerate lost gum tissue for a more even gum ... dark gum line treatment that can permanently lighten discolored ... total smile approach, which involves a personalized treatment plan to ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service offers ... Platinum Resistance Thermometers (SSPRTs) and industrial Resistance Temperature ... . . . guaranteed. Their metrology ... 200706-0), ISO 9001 and 17025 Certified and provides ... to 500°C, both ITS-90 and Callendar-van Dusen calibrations ...
(Date:3/2/2015)... 2015 Over the last five years ... vendors seeking to expand their geographic presence and achieve ... to reach $6.2 billion by 2019 at CAGR of ... the U.S. and Canada and a major part of ... regions such as Asia-Pacific including China and India, Latin ...
(Date:3/2/2015)... This year, the National Multiple Sclerosis Society’s annual awareness ... people across the country to unite, raise awareness, ... their best lives. MS Awareness Week is a special week ... the Society’s vision of a world free of MS. ... the central nervous system, interrupts the flow of information within ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased ... Health Plans: 2015 , the all-new 12th edition of ... plan market, with enrollment data and contact information for ... Available as a printed book containing the full directory ... tables and charts, as well as an electronic version, ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2
... users were informed of their odds for cardiovascular ... Letting patients know how cholesterol boosts their heart ... researchers report. , Researchers at McGill University in ... the study) with cholesterol problems who were instructed ...
... In the very first trial of its kind in ... find out if water softeners can help in the ... by clinicians at The University of Nottingham has received ... National Institute for Health Research (NIHR) Health Technology Assessment ...
... , McGill University researchers have uncovered the crucial role ... onset of breast cancer. The research, led by Dr. William ... Institute for Cancer Research in Scotland was published the ... Academy of Sciences (PNAS). The study,s first author is Dr. ...
... Net Income Increases 22% and Royalty Income Increases 29% ... ... Unilens Vision Inc. (OTC,Bulletin Board: UVICF) (TSX Venture Exchange: UVI), ... operating results for the first quarter of FY2008., Net sales, ...
... Switzerland, November 29 Biolytix AG,( http://www.biolytix.ch ... UK Ltd ( http://www.affymetrix.com ) and offers ... R&D community under conditions,compliant with a stringent ... the leading CRO,s for molecular biological analysis ...
... 29 BlueCross BlueShield of South,Carolina and ... have,streamlined access to international dental services through ... Healthcare Inc., Earlier this year, Companion ... members access to medical and surgical treatment,at ...
Cached Medicine News:Health News:Knowing Heart Risk Keeps Patients on Cholesterol Drugs 2Health News:Eczema sufferers test out benefits of water softeners 2Health News:Eczema sufferers test out benefits of water softeners 3Health News:McGill researchers link enzyme to breast cancer malignancy 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Earnings and Royalty Income 4Health News:Biolytix to Offer Industrial Gene Expression Analysis and Genotyping Services Using Affymetrix' GeneChip(R) Technology 2Health News:S.C. BlueCross, BlueChoice HealthPlan Expand Global Offerings to Include Dental Services 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
West lacrimal cannula blunt tip with side port....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Shahinian lacrimal cannula, bullet shaped tip, 0.3 mm side opening, straight....
Medicine Products: